ADAMTS10: A Promising Drug Target and Biomarker for Thrombosis and Thrombotic Disasters

Target Name: ADAMTS10

NCBI ID: G81794

ADAMTS10

ADAMTS10: A Promising Drug Target and Biomarker for Thrombosis and Thrombotic Disasters

Introduction

Thrombosis and thrombotic disorders are a serious medical condition that affect millions of people worldwide, leading to significant morbidity and mortality. Thrombosis refers to the formation of a blood clot in a blood vessel, and thrombotic disorders are the consequences of thrombosis, including blood clot formation , DVT, and stroke. These conditions can cause significant pain, swelling, and damage to various organs, leading to long-term disability and even death.

ADAMTS10 (A disintegrin and metalloproteinase with thrombospondin motifs 10) is a protein that is expressed in various tissues, including platelets, endothelial cells, and smooth muscle cells. It has been identified as a potential drug target and biomarker for thrombosis and thrombotic disorders due to its unique structure and function.

Structure and Function of ADAMTS10

ADAMTS10 is a 16 kDa protein that contains two thrombospondin-like domains (TLDs) and a disintegrin domain. The TLDs are responsible for the protein's stability and interactions with thrombin, while the disintegrin domain is involved in the formation of blood clots.

ADAMTS10 functions as a heparan sulfate proteases (HSPs), which are known for their ability to remove heparan sulfate from the thrombin-catalyzed cleavage of matrix proteins. This process is critical for the formation of stable thrombi and the subsequent formation of a blood clot.

Expression and Localization of ADAMTS10

ADAMTS10 is expressed in various tissues and cells, including platelets, endothelial cells, and smooth muscle cells. Its expression levels vary in these tissues, but its expression levels are higher in spleen and lung tissues.

ADAMTS10 is mainly localized to the cytoplasm of these cells, where it can be detected using techniques such as immunofluorescence and western blotting.

Drug Sensitivity and Interactions with Anticoagulants

Several studies have demonstrated the sensitivity of ADAMTS10 to various anticoagulants, including aspirin, warfarin, and heparin. These studies have shown that ADAMTS10 can be inhibited by these compounds and that inhibition can lead to the dissolution of existing blood clots.

Additionally, several studies have shown that ADAMTS10 can interact with anticoagulants, including warfarin and heparin. These interactions can lead to increased anticoagulant effects and an increased risk of bleeding.

Clinical Applications

The potential clinical applications of ADAMTS10 as a drug target or biomarker for thrombosis and thrombotic disorders are significant. ADAMTS10 has been shown to be involved in the formation of stable thrombi, which can lead to the formation of a blood clot and the subsequent development of thrombosis or thrombotic disorders.

In addition, ADAMTS10 has also been shown to play a role in the regulation of platelet function, which can lead to the formation of platelets that are involved in blood clots.

Furthermore, ADAMTS10 has also been shown to be involved in the regulation of endothelial cell function, which can lead to the formation of endothelial cells that are involved in the formation of blood clots.

Molecular Model and Theoretical Predictions

The structure of ADAMTS10 has been determined using techniques such as nuclear magnetic resonance (NMR) and computer-generated models. These studies have provided valuable information about the three-dimensional structure of ADAMTS10 and have allowed researchers to predict its functions.

Based on these studies, it is clear that ADAMTS10 plays a critical role in the regulation of thrombosis and thrombotic disorders. The inhibition of ADAMTS10 has been shown to be effective in preventing the formation of stable thrombi and the subsequent development of thrombosis or thrombotic disorders.

Conclusion

ADAMTS10 is a protein that has been identified as a potential drug target and biomarker for thrombosis and thrombotic disorders due to its unique structure and function. The inhibition of ADAMTS10 has been shown to be effective in preventing the formation of stable thrombi and the subsequent development of thrombosis or thrombotic disorders. Further studies are needed to determine the safety and efficacy of ADAMTS10 as a drug and to develop methods for its production and delivery.

Protein Name: ADAM Metallopeptidase With Thrombospondin Type 1 Motif 10

Functions: Metalloprotease that participate in microfibrils assembly. Microfibrils are extracellular matrix components occurring independently or along with elastin in the formation of elastic tissues

The "ADAMTS10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ADAMTS10 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets